Bayer may have
to ask shareholders for fresh capital to shore up its finances
even after the debt-laden German drugmaker slashed dividends
last week in its latest effort to get wiggle room,.
Bayer may have to ask shareholders for fresh capital to shore up its finances even after the debt-laden German drugmaker slashed dividends last week in its latest effort to get wiggle room, analysts said. But new CEO Bill Anderson may struggle to win over investors, who have seen the company's value sink by two thirds since its $63 billion acquisition of Monsanto in 2018, which saddled it with costly litigation and debt. The debate over a possible share issue comes as Anderson, who was hired last June to revive the company's fortunes, prepares to deliver a strategic investor update in London on Tuesday.
The FTSE 100 index closed Friday up 0.7% at 7627 points, lifted by commodities-exposed stocks and Astrazeneca, on the back of increased optimism among investors that the framework of a debt ceiling deal is starting to unfold "with more details expected. | 12:01pm
UK Retail Sales Proved Bright Spot Amid Inflation Pain 1151 GMT - U.K. retail-sales figures for April are modestly positive news, emerging from a difficult winter amid improving consumer. | May 26, 2023